CRISPR's Genetic Scissors Snip Away at Rare Diseases: A New Dawn for Millions

Clinical trials are transforming the treatment of rare genetic diseases, opening the door to revolutionary gene therapies. Advances in CRISPR-Cas9 gene editing and RNA therapies in recent times are yielding encouraging results for diseases such as spinal muscular atrophy and sickle cell anemia. The FDA-approved Zolgensma has already shown impressive success in SMA treatment. While projects like RealiseD are working towards streamlining clinical trials for ultra-rare diseases, which could potentially speed up drug development pipelines. As these new methods transition from the laboratory to the clinic, they hold promise for hundreds of millions of patients globally, turning previously lethal diseases into chronic conditions.

 

Sources: IHI, Medical Xpress, BW Healthcare World